Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore

Carrasco, Luis R and Lee, Linda K and Lee, Vernon J and Ooi, Eng Eong and Shepard, Donald S and Thein, Tun L and Gan, Victor and Cook, Alex R and Lye, David and Ng, Lee Ching and Leo, Yee Sin (2011): Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore. Published in: PLoS Neglected Tropical Diseases , Vol. 5, No. 12 (20 December 2011)

Abstract

Background: Dengue illness causes 50–100 million infections worldwide and threatens 2.5 billion people in the tropical and subtropical regions. Little is known about the disease burden and economic impact of dengue in higher resourced countries or the cost-effectiveness of potential dengue vaccines in such settings.

Methods and Findings: We estimate the direct and indirect costs of dengue from hospitalized and ambulatory cases in Singapore. We consider inter alia the impacts of dengue on the economy using the human-capital and the friction cost methods. Disease burden was estimated using disability-adjusted life years (DALYs) and the cost-effectiveness of a potential vaccine program was evaluated. The average economic impact of dengue illness in Singapore from 2000 to 2009 in constant 2010 US$ ranged between $0.85 billion and $1.15 billion, of which control costs constitute 42%–59%. Using empirically derived disability weights, we estimated an annual average disease burden of 9–14 DALYs per 100 000 habitants, making it comparable to diseases such as hepatitis B or syphilis. The proportion of symptomatic dengue cases detected by the national surveillance system was estimated to be low, and to decrease with age. Under population projections by the United Nations, the price per dose threshold for which vaccines stop being more cost-effective than the current vector control program ranged from $50 for mass vaccination requiring 3 doses and only conferring 10 years of immunity to $300 for vaccination requiring 2 doses and conferring lifetime immunity. The thresholds for these vaccine programs to not be cost-effective for Singapore were $100 and $500 per dose respectively.

Conclusions: Dengue illness presents a serious economic and disease burden in Singapore. Dengue vaccines are expected to be cost-effective if reasonably low prices are adopted and will help to reduce the economic and disease burden of dengue in Singapore substantially.

• Item Type: MPRA Paper
• Language: English
• Keywords: Health Economics, Dengue Vaccines, Cost-Effective Analysis
• Subjects: I - Health, Education, and Welfare > I1 - Health > I10 - General; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health; I - Health, Education, and Welfare > I1 - Health > I19 - Other

References

Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends in Microbiology 10: 100–103.

Gibbons RV, Vaughn DW (2002) Dengue: an escalating problem. British Medical Journal 324: 1563–1566.

Wilder-Smith A, Gubler DJ (2008) Geographic expansion of dengue: the impact of international travel. Medical Clinics of North America 92: 1377–1390.

Ooi E-E, Gubler DJ (2009) Global spread of epidemic dengue: the influence of environmental change. Future Virology 4: 571–580.

Halstead SB (2007) Dengue. The Lancet 370: 1644–1652.

WHO (2002) Weekly Epidemiological Record. World Health Organization. Available: http://www.who.int/docstore/wer/pdf/2002/wer7736.pdf. Accessed 2011 Nov 4.

Anez G, Balza R, Valero N, Larreal Y (2006) Economic impact of dengue and dengue hemorrhagic fever in the State of Zulia, Venezuela, 1997–2003. Revista Panamericana De Salud Publica-Pan American Journal of Public Health 19: 314–320.

Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, et al. (2008) Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. American Journal of Tropical Medicine and Hygiene 79: 364–371.

Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ (1998) Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994. American Journal of Tropical Medicine and Hygiene 59: 265–271.

Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, et al. (2009) Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. American Journal of Tropical Medicine and Hygiene 80: 846–855.

Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH (2011) Economic impact of dengue illness in the americas. American Journal of Tropical Medicine and Hygiene 84: 200–207.

Shepard DS (2010) Cost and burden of dengue and chikungunya from the Americas to Asia. Dengue Bulletin World Health Organization 34.

Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, et al.(2007) Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 369: 1452–1459.

Cho Min N (2000) Assessment of dengue hemorrhagic fever in Myanmar. Southeast Asian J Trop Med Public Health 31: 636–641.

Garg P, Nagpal J, Khairnar P, Seneviratne SL (2008) Economic burden of dengue infections in India. Transactions of the Royal Society of Tropical Medicine and Hygiene 102: 570–577.

Clark DV, Mammen MP, Nisalak A, Puthimethee V, Endy TP (2005) Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. American Journal of Tropical Medicine and Hygiene 72:786–791.

Harving ML, Ronsholt FF (2007) The economic impact of dengue hemorrhagic fever on family level in Southern Vietnam. Danish Medical Bulletin 54: 170–172.

Ooi EE, Goh KT, Gubler DJ (2006) Denque prevention and 35 years of vector control in Singapore. Emerging Infectious Diseases 12: 887–893.

Goh K (1995) Changing epidemiology of dengue in Singapore. The Lancet 346:1098.

Low JG, Ooi EE, Tolfvenstam T, Leo YS, Hibberd ML, et al. (2006) Early Dengue infection and outcome study (EDEN) - study design and preliminary findings. Ann Acad Med Singapore 35: 783–789.

Standish K, Kuan G, Avile´s W, Balmaseda A, Harris E (2010) High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl Trop Dis 4: e633.

Dechant E, Rigau-Perez J (1999) Hospitalizations for suspected dengue in Puerto Rico, 1991–1995: estimation by capture-recapture methods. The Puerto Rico Association of Epidemiologists. Am J Trop Med Hyg 61: 574–578.

Keating J (2001) An investigation into the cyclical incidence of dengue fever. Social Science & Medicine 53: 1587–1597.

Fuller DO, Troyo A, Beier JC (2009) El Nino Southern Oscillation and vegetation dynamics as predictors of dengue fever cases in Costa Rica. Environmental Research Letters 4: 140111–140118.

Beatty ME, Beutels P, Meltzer MI, Shepard DS, Hombach J, et al. (2011) Health economics of dengue: a systematic literature review and expert panel’s assessment. Am J Trop Med Hyg 84: 473–488.

Guy B, Nougarede N, Begue S, Sanchez V, Souag N, et al. (2008) Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirusprimed subjects. Vaccine 26: 5712–5721.

Durbin AP, Whitehead SS (2010) Dengue vaccine candidates in development. Current Topics in Microbiology and Immunology 338: 129–143.

Ministry of Health of Singapore (2011) MOH weekly publication of statistics on local infectious disease situation. Available: http://www.moh.gov.sg/content/ moh_web/home/statistics/infectiousDiseasesStatistics/weekly_infectiousdiseasesbulletin.html. Accessed 2011 Nov 4.

WHO (2011) Annual Dengue Data in the Western Pacific Region. Available: http://www.wpro.who.int/health_topics/dengue/data.htm. Accessed 2011 Nov 4.

Low J, Ong A, Tan L, Chaterji S, Chow A, et al. (2011) The early clinical features of dengue in adults: challenges for early clinical diagnosis. PLoS Negl Trop Dis 5: e1191.

Duarte HHP, Franca EB (2006) Data quality of dengue epidemiological surveillance in Belo Horizonte, Southeastern Brazil. Revista De Saude Publica 40: 134–142.

Yew YW, Ye T, Ang LW, Ng LC, Yap G, et al. (2009) Seroepidemiology of dengue virus infection among adults in Singapore. Ann Acad Med Singapore 38:667–675.

Egger JR, Coleman PG (2007) Age and clinical dengue illness. Emerging Infectious Diseases 13: 924–925.

Porter KR, Beckett CG, Kosasih H, Tan RI, Alisjahbana B, et al. (2005) Epidemiology of dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung, West Java, Indonesia. Am J Trop Med Hyg 72: 60–66.

Beckett CG, Kosasih H, Faisal I, Nurhayati, Tan R, et al. (2005) Early detection of dengue infections using cluster sampling around index cases. Am J Trop Med Hyg 72: 777–782.

Ministry of Health of Singapore (2010) Healthcare financing. Hospital bill size. Singapore Ministry of Health. Dengue age,60. Available: http://www.moh.gov.sg/content/moh_web/home/costs_and_financing/HospitalBillSize/dengue_age_60_.html. Accessed: 2011 Nov 4.

WHO (2008) WHO Guide for standardization of economic evaluations of immunization programmes: immunizations, vaccines, and biologicals. World Health Organization. Available: http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.14_eng.pdf. Accessed: 2011 Nov 4.

Koopmanschap MA, Rutten FFH, Vanineveld BM, Vanroijen L (1995) The friction cost method for measuring indirect costs of disease. Journal of Health Economics 14: 171–189.

Ministry of Education (2010) Education Statistics Digest 2010. , Singapore: Ministry of Education of Singapore.

Grosse SD (2003) Productivity loss tables. In: Haddix AC, Teutsch SM, Shaffer PA, Dun˜et DO, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. Oxford; New York: Oxford University Press.

Murray CJL (1994) Quantifying the burden of disease - the technical basis for disability-adjusted life years. Bulletin of the World Health Organization 72: 429–445.

Gubler DJ, Meltzer M (1999) Impact of dengue/dengue hemorrhagic fever on the developing world. In: Karl Margniorosch FAM, Aaron JShatkin, eds. Advances in Virus Research Academic Press. pp 35–70.

World Health Organization (2008) The Global Burden of Disease 2004 Update. Geneva: World Health Organization.

Lum LC, Suaya JA, Tan LH, Sah BK, Shepard DS (2008) Quality of life of dengue patients. Am J Trop Med Hyg 78: 862–867.

EuroQol Group (1990) Euroqol-a new facility for the measurement of healthrelated quality of life. Health Policy 16: 199–208.

Shepard DS, Halstead SB (1993) Dengue (with notes on yellow fever and Japanese encephalitis). In: Jamison DT, Mosley WH, Measham AR, J.L. B, eds. Disease Control Priorities for Developing Countries. New York: Oxford University Press for the World Bank. pp 303–320.

Sachs JD (2001) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, Switzerland, 2001. Available: http:// whqlibdoc.who.int/publications/2001/924154550X.pdf. Accessed 2011 Nov 4.

UN (2011) World Population Prospects, the 2010 Revision. United Nations, Department of Economic and Social Affairs. Available: http://esa.un.org/unpd/wpp/Excel-Data/population.htm. Accessed 2011 Nov 4.

Hsieh YH, Ma S (2009) Intervention measures, turning point, and reproduction number for dengue, Singapore, 2005. American Journal of Tropical Medicine and Hygiene 80: 66–71.

Anderson RM, May RM Infectious diseases of humans: dynamics & control: Oxford University Press.

World Health Organization (1996) The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Atlanta, GA: World Health Organization.

Shepard DS, Suaya JA (2010) Cost-effectiveness of a dengue vaccine in Southeast Asia and Panama: preliminary estimates. Handbook of Disease Burdens and Quality of Life Measures Part 2 2.5: 1281–1296.

Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, et al. (2004) Costeffectiveness of a pediatric dengue vaccine. Vaccine 22: 1275–1280.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, et al. (2011) Costeffectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 29: 6686–6694.

Chow ALP, Leo YS, Tan LK, Lye DC, Lin L, et al. (2009) Chikungunya outbreak, Singapore, 2008. Emerging Infectious Diseases 15: 836–837.

Atkinson MP, Su Z, Alphey N, Alphey LS, Coleman PG, et al. (2007) Analyzing the control of mosquito-borne diseases by a dominant lethal genetic system. Proceedings of the National Academy of Sciences 104: 9540–9545.

Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, et al. (2011) Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 476: 454–457.

Lye D, Lee V, Sun Y, Leo Y (2010) The benign nature of acute dengue infection in hospitalised older adults in Singapore. Intl Journal of Infectious Diseases 14 e410–e413.

Low J, Ong A, Tan L, Chaterji S, Chow A, et al. (In press) The early clinical features of dengue in adults: challenges for early clinical diagnosis. PLoS Negl Trop Dis.

WHO (2009) WHO Guide to identifying the economic consequences of disease and injury. Geneva: World Health Organization.

Luz PM, Grinsztejn B, Galvani AP (2009) Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health 14: 237–246.

Land Transport Authority (2010) Singapore Land Transport Statistics in Brief 2010. Singapore.

World Bank (2009) GDP per capita (current US$). Available: http://data.worldbank.org/data-catalog. Accessed 2011 Nov 4.

Ling Ang K, Foo S (2002) An exploratory study of eating patterns of Singapore children and teenagers. Health Education 102: 239–248.

Ministry of Community Youth and Sports of Singapore (2006) Report on the Ageing Population. Committee on Ageing Issues. Ministry of Community Youth and Sports of Singapore. Available: http://app1.mcys.gov.sg/Portals/0/Summary/ research/CAI_report.pdf. Accessed 2011 Nov 4.

May AD (2004) Singapore: The Development of a World Class Transport System. Transport Reviews 24: 79–101.